Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.21, $0.12 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $97.23 million versus the consensus estimate of $103.55 million.

GUIDANCE:

Ironwood Pharma reiterates FY2022 revenue of $420-$430 million, versus the consensus of $428.80 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• BofA lists top 5 themes driving next $1tn in incremental semi sales